联合检测NSE、S100B、hs-CRP及NIHSS评分对急性脑梗死患者病情严重程度的评估价值

目的探讨联合检测神经元特异性烯醇化酶(NSE)、 S100B、超敏C-反应蛋白(hs-CRP)及美国国立卫生研究院卒中量表(NIHSS)评分对急性脑梗死患者病情严重程度的评估价值。方法选取我院2019年1月至2020年3月收治的急性脑梗死患者80例,依据改良Rankin量表(mRS)评分将其分为重度组(mRS评分≥3分,n=36)及轻度组(mRS评分<3分,n=44);另选取同期在我院行健康体检的40例患者作为健康组。比较三组的NSE、 S100B、 hs-CRP及NIHSS评分。结果重度组的NSE、 S100B、 hs-CRP、 NIHSS评分均高于轻度组及健康组(P <0.05);Pearson分析显示,NSE、 S100B、 hs-CRP及NIHSS评分与急性脑梗死病情严重程度呈正相关(r>0, P <0.05)。结论 NSE、 S100B、 hs-CRP及NIHSS评分与急性脑梗死患者病情严重程度呈正相关,联合检测具有客观性。     

老年难治性心力衰竭患者BNP、hs-CRP水平与心功能的相关性及其临床意义

【摘要】目的：探究老年难治性心力衰竭（心衰）患者BNP、hs-CRP水平与心功能的相关性及其临床意义。方法：以我院心内科近两年收治的61例老年难治性心衰患者为临床研究对象，作为心衰组，另选20例健康志愿者作为对照组。心衰组患者按照NYHA分级的不同，从低到高分成A、B、C三组。对患者进行BNP与hs-CRP测定，并测定患者的心功能LVDD和LVEF。跟踪记录患者的心血管事件发生情况，比较患者BNP、hs-CRP、LVEF、LVDD水平的差异。结果：与对照组相比，心衰组患者的LVDD、BNP与hs-CRP指标显著较高而LVEF指标显著较低；A、B、C三组患者的LVDD、BNP与hs-CRP指标逐渐升高、LVEF水平逐渐下降；与无心血管事件患者相比，出现心血管事件患者的BNP、hs-CRP、LVDD水平显著较高，LVEF指标则显著低。差异均具有统计学意义（P＜0.05）。结论：BNP与hs-CRP指标与老年难治性患者的心功能具有密切的关系，BNP、hs-CRP以及患者的LVEF、LVDD水平是临床诊断老年难治性心衰的重要标志物，具有重要的临床诊断价值。     

金纳多对突发性耳聋患者血流动力学的影响

目的:探讨金纳多对突发性耳聋患者血清hs-CRP、HMGB1、ADP、RES及血流动力学的影响。方法:将2009年8月～2012年5月收治的78例突发性耳聋患者随机分为对照组(常规治疗组)和观察组(加用金多纳组),每组各39例,将两组不同严重程度者治疗前及治疗后10d、20d血清hs-CRP、HMGB1、ADP、RES及血流动力学指标进行比较。结果:观察组轻度、中度及重度者治疗后基底动脉血流动力学指标异常率低于对照组,hs-CRP、HMGB1、ADP、RES改善幅度大于对照组,P均<0.05。结论:金纳多可有效改善突发性耳聋者的hs-CRP、HMGB1、ADP、RES及血流动力学。     

Evaluation of inflammation during fixed orthodontic treatment

ObjectiveThe aim of this study was to assess effects of fixed orthodontic therapy on high-sensitivity C-reactive protein (hs-CRP) level, CBC parameters and levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT), gamma glutamyl transferase (GGT), alkaline phosphatase (ALP), urea, creatinine, sodium (Na), potassium (K), calcium (Ca), total protein (TP), and albumin (Alb).DesignBlood samples (7 ml) were drawn at baseline, on days 1 and 7, and three months after placement of braces in the study group, while only one blood sample was drawn at baseline in the control group. Serum hs-CRP levels were measured by nephelometric method. Friedman two-way variance analysis was used to assess values with skewed distribution obtained at baseline, on days 1 and 7, in the third month. Wilcoxon rank sign test was performed if median values were unequal.ResultsDuring measurement periods, there were significant increases in hs-CRP level, WBC count and neutrophil count while a significant decrease in Na level (p < 0.05). K level was significantly decreased on the day 1. No significant differences were detected in other biochemical parameters evaluated.ConclusionElevation in serum hs-CRP levels and neutrophil: lymphocyte ratio within first 3 months indicates that a systemic immune response develops against therapy in patients undergoing fixed orthodontic therapy.     

糖代谢异常者血脂、hs-CRP的表达水平及其临床意义

目的：分析糖代谢异常者血脂、hs-CRP表达水平及临床意义。方法采用回顾性方法分析,选取该院自2012年10月—2014年10月期间口服糖耐量试验患者172例,将其分为对照组(正常糖耐量)、观察组(葡萄糖调节异常),两组各86例,比较两组的血脂各项指标及hs-CRP表达水平。结果观察组血脂水平及hs-CRP水平与对照组相比差异有统计学意义(P<0.05);且各项血脂指标、hs-CRP检出率高于对照组(<0.05)。结论高TG、高LDL-C 是糖代谢异常者血脂代谢的典型特征,联合CHO、HDL-C、hs-CRP各项指标可以评估糖尿病及其相关疾病患者的心血管受损情况,对于糖尿病合并冠心病患者的早期诊治、预后评价有重要意义。     

Effect of Resveratrol Supplementation on Inflammatory Markers: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Purpose

The evidence has suggested that resveratrol has anti-inflammatory effect; however, the results are inconsistent and inconclusive. The aim of this study was to assess the effect of resveratrol supplementation on the levels of inflammatory markers through a systematic review and meta-analysis of available randomized controlled trials (RCTs).

辛伐他汀联合普罗布考治疗缺血性脑卒中对患者血清 hs－CRP、FT3、FT4水平的影响

目的：观察辛伐他汀联合普罗布考治疗缺血性脑卒中对患者血清超敏C反应蛋白（ hs－CRP）、游离三碘甲状腺原氨酸（ FT3）、甲状腺素（ FT4）水平的影响。方法将107例缺血性脑卒中患者随机分为试验组54例和对照组53例。试验组给予辛伐他汀联合普罗布考治疗,对照组仅给予普罗布考治疗,连续治疗21d。比较2组患者治疗前后血清hs－CRP、FT3、FT4变化。结果治疗前2组患者血清hs－CRP、FT3、FT4水平差异无统计学意义（ P＞0．05）。治疗后2组患者hs－CRP均有所降低,但试验组患者降低幅度大于对照组,差异均有统计学意义（ P＜0．05）;治疗后2组FT3、FT4水平均增高,但试验组患者增幅大于对照组,差异均有统计学意义（P＜0．05）。结论辛伐他汀联合普罗布考治疗缺血性脑卒中可显著降低患者血清hs－CRP水平,增高FT3、FT4水平,使其趋于正常水平。     

Simvastatin reduces plasma concentration of high-sensitivity C-reactive protein in type 2 diabetic patients with hyperlipidemia

High-sensitivity C-reactive protein (hs-CRP) is positively associated with the prevalence of coronary artery disease by epidemiologic data. Prospective studies indicate that 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors reduced the plasma hs-CRP concentration and the risk of recurrent coronary events after myocardial infarction. Type 2 diabetes is associated with high mortality risk of coronary heart disease and this high risk may be involved in the inflammatory factors. We have therefore conducted a prospective study to assess whether simvastatin can rapidly reduce the plasma hs-CRP concentration in type 2 diabetic patients with hyperlipidemia. Seventeen type 2 diabetic patients with hyperlipidemia were enrolled in the study after 6 weeks on a lipid-lowering diet. Fourteen patients completed the study, taking simvastatin 20 mg daily for 8 weeks. Fasting blood samples were collected from each patient before and after 8-week administration of simvastatin. In response to 8-week administration of simvastatin, hs-CRP levels significantly decreased from 0.312±0.057 to 0.193±0.045 mg/dl (P<.01). Plasma LDL cholesterol also decreased significantly from 130±9 to 74±3 mg/dl (P=.001). This study shows that plasma hs-CRP concentration can be reduced by 8-week administration of simvastatin in type 2 diabetic patients with hyperlipidemia.     

肠炎宁糖浆联合头孢克肟治疗小儿急性肠胃炎的临床研究

目的探讨肠炎宁糖浆联合头孢克肟干混悬剂治疗小儿急性肠胃炎的临床疗效。方法选取2017年7月—2019年7月在宝鸡市妇幼保健院治疗的急性肠胃炎患儿82例,根据用药的差别分为对照组(41例)和治疗组(41例)。对照组口服头孢克肟干混悬剂,1.5～3 mg/kg,2次/d;治疗组在对照组基础上口服肠炎宁糖浆,10 mL/次,3次/d。两组患儿均经7 d。观察两组患者临床疗效,同时比较治疗前后两组患者临床症状改善时间,以及血清超敏C反应蛋白(hs-CRP)、白细胞介素-6(IL-6)和降钙素(PCT)水平。结果治疗后,对照组临床有效率为80.49%,显著低于治疗组的97.56%,两组比较差异具有统计学意义(P0.05)。治疗后,治疗组患儿腹痛缓解时间、发热缓解时间、呕吐缓解时间、腹泻缓解时间均明显短于对照组(P0.05)。治疗后,两组患者血清hs-CRP、IL-6、PCT水平均明显下降(P0.05),且治疗组患者明显低于对照组(P0.05)。结论肠炎宁糖浆联合头孢克肟干混悬剂治疗小儿急性肠胃炎可有效改善患儿临床症状,降低机体炎症反应,具有一定的临床推广应用价值。     

替格瑞洛联合瑞舒伐他汀对急性ST抬高心肌梗死患者心功能和血清学指标的影响

目的 探讨替格瑞洛联合瑞舒伐他汀对急性ST抬高心肌梗死患者心功能和血清学指标的影响。方法 选择2018年1月—2019年5月选择在宝鸡市中医医院诊治的急性ST段抬高型心肌梗死患者150例作为研究对象,根据随机数字表法将患者分为对照组和观察组,每组各75例。对照组患者在经皮冠状动脉介入治疗（PCI）术前7 d和术后口服瑞舒伐他汀钙片,10 mg/d。观察组在对照组治疗的基础上口服替格瑞洛片,90 mg/次,1次/d。两组均治疗观察3个月。比较两组患者治疗前后的6 min步行距离（6 MWT）、左室舒张末期内径（LVEDD）、左室收缩末期内经（LVESD）、左室间隔厚度（LVIVS）、左心室后壁厚度（LVPWT）、N末端脑钠肽原（NT-proBNP）和超敏C反应蛋白（hs-CRP）水平和主要心血管事件（MACE）发生情况。结果 两组治疗后的6 MWT值都显著高于治疗前（P<0.05）,且观察组高于对照组（P<0.05）。两组治疗前后的LVEDD、LVESD、LVIV、LVPWT对比无统计学意义。两组治疗后的血清NT-proBNP、hs-CRP水平都显著低于治疗前（P<0.05）,且观察组低于对照组（P<0.05）。观察组治疗期间的MACE发生率为5.3%,显著低于对照组的18.7%（P<0.05）。结论 替格瑞洛联合瑞舒伐他汀治疗急性ST抬高心肌梗死能抑制NT-proBNP、hs-CRP的释放,提高患者的6 MWT值,减少MACE的发生。